Patents Assigned to CLINICAL GENOMICS PTY. LTD.
-
Publication number: 20140155280Abstract: The present invention relates generally to a method for screening a subject for the onset, predisposition to the onset and/or progression of a colorectal neoplasm by screening for modulation in the level of expression of one or more nucleic acid markers. More particularly, the present invention provides a method for screening a subject for the onset, predisposition to the onset and/or progression of a colorectal neoplasm by screening for modulation in the level of expression of one or more gene markers in membranous microvesicles. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosing and/or monitoring of colorectal neoplasms, such as colorectal adenoma and adenocarcinomas.Type: ApplicationFiled: May 4, 2012Publication date: June 5, 2014Applicants: Commonwealth Scientific and Industrial Research Organisation, Clinical Genomics Pty. Ltd.Inventors: Lawrence Charles Lapointe, Susanne Kartin Pedersen, Peter Molloy
-
Patent number: 8669050Abstract: The present invention relates generally to novel nucleic acid molecules, the levels and/or patterns of expression of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm and to derivatives, homologues or analogues of said molecules. More particularly, the present invention is directed to novel nucleic acid molecules, the levels of expression of which are indicative of the onset and/or progression of a gastrointestinal tract neoplasm, such as an adenoma, and to derivatives, homologues or analogues of said molecules. The present invention is further directed to isolated proteins encoded thereby and to derivatives, homologues, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of prophylactic, therapeutic and/or diagnostic applications including, but not limited to, those relating to the diagnosis and/or treatment of colorectal neoplasms such as colorectal adenomas.Type: GrantFiled: March 12, 2004Date of Patent: March 11, 2014Assignee: Clinical Genomics Pty. Ltd.Inventors: Robert James, Julianne Henry, Jan Kazenwadel, Nick Van Host Pellekaan, Anne MacPherson, Susan O'Connor
-
Publication number: 20130338020Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.Type: ApplicationFiled: September 13, 2011Publication date: December 19, 2013Applicants: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, CLINICAL GENOMICS PTY. LTD.Inventors: Jason Peter Ross, Michael Buckley, Peter Laurence Molloy, Susan Margaret Mitchell, Konsta Rainer Duesing, Zheng-Zhou Xu
-
Publication number: 20120115167Abstract: A method for isolating a target bioentity from a biological sample, comprises contacting the biological sample with a magnetically-labelled ligand having selective binding affinity for the target bioentity, or for a determinant on the target bioentity, to form a target bioentity/labelled ligand complex, locating a separation module having a defined fluid flow path in the magnetic field of a magnetic module, the magnetic module comprising an array of at least two magnets in which adjacent magnets in the array are aligned with opposing polarity; passing the biological sample through the separation module to subject the biological sample to the magnetic field while the sample is passing through the defined fluid flow path to magnetically capture the target bioentity/labelled ligand complex by arresting or hindering movement of the complex within the defined fluid flow path; removing the separation module from the magnetic field; and recovering the target bioentity/labelled ligand complex from the fluid flow pathType: ApplicationFiled: April 22, 2010Publication date: May 10, 2012Applicant: CLINICAL GENOMICS PTY. LTD.Inventors: Howard Milne Chandler, Michael Bruce Chandler
-
Publication number: 20110160072Abstract: The present invention relates generally to a nucleic acid molecule, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a large intestine neoplasm. More particularly, the present invention is directed to a nucleic acid molecule, the expression profiles of which are indicative of the onset and/or progression of a colorectal neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenomas and adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a large intestine neoplasm by screening for modulation in the expression profile of said nucleic acid molecule markers.Type: ApplicationFiled: October 23, 2008Publication date: June 30, 2011Applicants: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence Charles Lapointe, Robert Dunne, GraƩme P. Young, Peter Molloy, Susanne Pedersen, Glenn Southwell Brown, Lloyd Douglas Graham
-
Publication number: 20110098189Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas.Type: ApplicationFiled: October 23, 2008Publication date: April 28, 2011Applicants: CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence C. Lapointe, Robert Dunne, Graeme P. Young, Trevor John Lockett, William J. Wilson, Peter Laurence Molloy
-
Publication number: 20100292094Abstract: The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.Type: ApplicationFiled: October 23, 2008Publication date: November 18, 2010Applicants: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence Charles Lapointe, Robert Dunne, Graeme P. Young, Trevor John Lockett, William J. Wilson
-
Publication number: 20090325810Abstract: The present invention relates generally to an array of nucleic acid molecules, the expression profiles of which characterise the anatomical origin of a cell or population of cells within the large intestine. More particularly, the present invention relates to an array of nucleic acid molecules, the expression profiles of which characterise the proximal or distal origin of a cell or population of cells within the large intestine. The expression profiles of the present invention are useful in a range of applications including, but not limited to determining the anatomical origin of a cell or population of cells which have been derived from the large intestine.Type: ApplicationFiled: May 22, 2007Publication date: December 31, 2009Applicant: CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence C. Lapointe, Robert Dunne